On the evening of February 28th, 2023, on the banks of the fragrant harbor, with a gentle breeze blowing, to welcome and celebrate the visit of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) delegation to Hong Kong, and to enhance and promote the exchange and integration of the biopharmaceutical industry between Hong Kong and the mainland, especially the Greater Bay Area, member unit of PhIRDA, ZSHK LABORATORIES LIMITED. (ZSHK), hosted a reception banquet. Colleagues from the medical industry in both regions gathered together to discuss industry insights.
The banquet specifically invited nearly 100 medical industry partners from the mainland and Hong Kong, including Pro.Sun Dong, the Secretary for Innovation and Technology of the HKSAR, Mr. Lv Feng, Deputy Minister of the Economic Department of the Liaison Office of the Central People's Government in the HKSAR, Mr. Qiu Da Gen, member of the Hong Kong Legislative Council, Mr. Lin Wen Jian, Director of the Hong Kong Department of Health,Pro. Lu Yu Lin, founding president of the HKBMIA, Mr. Huang Keqiang, CEO of HKSTP, and Zheng Guangting, Vice President of the HKUST. The delegation was very concerned about issues such as how to use the resource advantages of both regions to promote the development of Hong Kong's biopharmaceutical industry, strengthen industrial exchanges between the two regions, promote the common development of the biopharmaceutical industry in the GBA, financing in capital markets, government policies to encourage industrial development, and enterprise R&D cooperation.
Mr. Hu Dingxu, Chairman of the Board of Directors of ZSHK, mentioned in his welcoming speech that one year before the outbreak of the COVID-19 pandemic, President Song Ruilin led a delegation to visit Hong Kong, which facilitated the landing of ZSHK in Hong Kong. ZSHK has joined forces with HKSTP Corporation to build a critical basic platform for the transformation of biopharmaceuticals, which will also be the first GLP (Good Laboratory Practice) institution in Hong Kong that meets global regulatory standards such as those of China, the United States, and Europe. It will help Hong Kong build itself into a highland of biopharmaceutical innovation in the GBA and provide solid guarantees for promoting the transformation of scientific research results and talent training.
PRO.Sun Dong, The Secretary for Innovation, Technology and Industry of the HKSAR, Lin Wen Jian, Director of the Department of Health, and Qiu Da Gen, Legislative Council Member, congratulated ZSHK on its achievements in their speeches and warmly welcomed the delegation's visit. They hoped that the industrial cooperation between the two regions would be more closely linked to promote industrial development.
Ms. Liang Yingyu, a director of ZSHK, a managing partner of Qiming Venture Partners, and chairman of the Investment Committee of the PhIRDA, congratulated the delegation on their visit to Hong Kong and their fruitful achievements. She said that the core members of ZSHK come from the mainland and have started businesses in Hong Kong, becoming a bridge and link connecting the biopharmaceutical innovation development between Hong Kong and the mainland with practical actions.
Mr. Song Ruilin, the Executive President of PhIRDA, stated in his speech that the delegation of the PhIRDA has gained a lot from their two-day visit to Hong Kong. The visiting delegation had in-depth exchanges with relevant government departments, universities, and scientific innovation parks. ZSHK is a member unit of PhIRDA, and has witnessed its growth. It is hoped that in the future, ZSHK can closely link the medical industry of the two places and help promote the innovative development of the medical industry in both places.
During the banquet, guests spoke freely and exchanged warmly, expressing their expectations for Hong Kong to become a highland for biopharmaceutical innovation in China, attracting overseas high-level talents, and establishing a high-level medical innovation ecology. Members of the visiting delegation expressed their willingness to strengthen substantial cooperation between the Mainland and Hong Kong in talent cultivation, capital financing support, scientific research achievement transfer and transformation, and academic exchanges.
In the three years since the outbreak of the Covid-19, ZSHK has established independent GLP laboratories in Suzhou Industrial Park, Suzhou City, Jiangsu Province, and in Pingshan District, Shenzhen, Guangdong Province. It has also established a complete experimental animal supply chain in Guangxi and Hunan Province.
